Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sat · 31 Oct 2026
Promising but preliminary

Intralesional cemiplimab for patients with early-stage cutaneous squamous cell carcinoma: Results from a dose-escalation study with expansion cohorts.

Low-dose intralesional cemiplimab showed antitumor activity against early-stage skin cancer with manageable side effects, though findings involve a small patient group.

This dose-escalation study with expansion cohorts examined efficacy and safety of low-dose intralesional cemiplimab. Intralesional cemiplimab showed antitumor activity with an acceptable safety profile, but the small cohort limits generalizability.

What the study was

Study design
Dose-escalation study with expansion cohorts
Population
patients with early-stage cutaneous squamous cell carcinoma
Category
Treatment Innovation
Maturity
Exploratory
Journal
Journal of the American Academy of Dermatology

Why it surfaced

Retained as a standard-priority dose-escalation study with expansion cohorts after PubMed abstract review; the score reflects clinical relevance, design strength, novelty, and population need under the v1.3 conservative rubric.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.